TuHURA Biosciences (NASDAQ:HURA) Releases Quarterly Earnings Results

TuHURA Biosciences (NASDAQ:HURA) posted its quarterly earnings data on Friday. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04, FiscalAI reports.

TuHURA Biosciences Stock Down 4.3%

HURA stock traded down $0.06 during midday trading on Friday, reaching $1.39. 371,847 shares of the company were exchanged, compared to its average volume of 853,995. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.18 and a current ratio of 0.18. The stock’s 50-day simple moving average is $1.93 and its 200 day simple moving average is $2.00. The company has a market cap of $88.43 million, a price-to-earnings ratio of -2.57 and a beta of -0.23. TuHURA Biosciences has a 1-year low of $0.41 and a 1-year high of $3.43.

Wall Street Analyst Weigh In

HURA has been the subject of several recent research reports. Citizens Jmp reiterated a “market outperform” rating and issued a $9.00 price objective on shares of TuHURA Biosciences in a research note on Tuesday, August 18th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a report on Tuesday, October 27th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, October 15th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research focuses on treatments intended to stimulate the immune system and address mechanisms that allow tumors to evade immune attack. The company’s pipeline includes IFx-2.0, an investigational intratumoral immunotherapy being studied for use with checkpoint inhibitors, as well as antibody programs targeting immune-regulating pathways. TuHURA has no marketed products, and its candidates remain in development.